Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Vulvovaginal Candidiasis Treatment Market, by Distribution Channel
1.4.2 North America Vulvovaginal Candidiasis Treatment Market, by Route of Administration
1.4.3 North America Vulvovaginal Candidiasis Treatment Market, by Drug Class
1.4.4 North America Vulvovaginal Candidiasis Treatment Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. North America Vulvovaginal Candidiasis Treatment Market by Distribution Channel
3.1 North America Retail Pharmacy Market by Country
3.2 North America Hospital Pharmacy Market by Country
3.3 North America Online Pharmacy Market by Country
Chapter 4. North America Vulvovaginal Candidiasis Treatment Market by Route of Administration
4.1 North America Oral Market by Country
4.2 North America Intravenous Market by Country
4.3 North America Topical Market by Country
Chapter 5. North America Vulvovaginal Candidiasis Treatment Market by Drug Class
5.1 North America Fluconazole Market by Country
5.2 North America Clotrimazole Market by Country
5.3 North America Terconazole Market by Country
5.4 North America Terbinafine Market by Country
5.5 North America Nystatin Market by Country
5.6 North America Ketoconazole Market by Country
5.7 North America Others Market by Country
Chapter 6. North America Vulvovaginal Candidiasis Treatment Market by Country
6.1 US Vulvovaginal Candidiasis Treatment Market
6.1.1 US Vulvovaginal Candidiasis Treatment Market by Distribution Channel
6.1.2 US Vulvovaginal Candidiasis Treatment Market by Route of Administration
6.1.3 US Vulvovaginal Candidiasis Treatment Market by Drug Class
6.2 Canada Vulvovaginal Candidiasis Treatment Market
6.2.1 Canada Vulvovaginal Candidiasis Treatment Market by Distribution Channel
6.2.2 Canada Vulvovaginal Candidiasis Treatment Market by Route of Administration
6.2.3 Canada Vulvovaginal Candidiasis Treatment Market by Drug Class
6.3 Mexico Vulvovaginal Candidiasis Treatment Market
6.3.1 Mexico Vulvovaginal Candidiasis Treatment Market by Distribution Channel
6.3.2 Mexico Vulvovaginal Candidiasis Treatment Market by Route of Administration
6.3.3 Mexico Vulvovaginal Candidiasis Treatment Market by Drug Class
6.4 Rest of North America Vulvovaginal Candidiasis Treatment Market
6.4.1 Rest of North America Vulvovaginal Candidiasis Treatment Market by Distribution Channel
6.4.2 Rest of North America Vulvovaginal Candidiasis Treatment Market by Route of Administration
6.4.3 Rest of North America Vulvovaginal Candidiasis Treatment Market by Drug Class
Chapter 7. Company Profiles
7.1 Bayer AG
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.2 Pfizer, Inc.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional & Segmental Analysis
7.2.4 Research & Development Expense
7.3 Bristol Myers Squibb Company
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional Analysis
7.3.4 Research & Development Expenses
7.4 Astellas Pharma, Inc.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expense
7.5 Mycovia Pharmaceuticals, Inc. (NovaQuest Capital Management, LLC)
7.5.1 Company Overview
7.5.2 Recent strategies and developments:
7.5.2.1 Trials and Approvals:
7.6 Basilea Pharmaceutica Ltd.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expenses
7.7 Scynexis, Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Research & Development Expenses
7.7.4 Recent strategies and developments:
7.7.4.1 Trials and Approvals:
7.8 Grupo Ferrer Internacional S.A.
7.8.1 Company Overview
Unique Offerings 
